{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:08:33Z","timestamp":1771459713329,"version":"3.50.1"},"reference-count":19,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2014,9,5]]},"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study is a European multicentre, randomised, double-blind, placebo-controlled trial investigating the efficacy and safety of nilvadipine as a disease course modifying treatment for mild-to-moderate Alzheimer's disease (AD) in a phase III study that will run for a period of 82\u2005weeks with a treatment period of 78\u2005weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Adult patients, males and females over 50\u2005years with mild-to-moderate AD as defined by the National Institute of Neurological and Communicative Disorders and Stroke\/Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA) criteria, will be included in the study. It aims to recruit a total of 500 patients with AD; 250 in the nilvadipine group and 250 in the placebo group. Participants will be randomised to receive nilvadipine, an 8\u2005mg overencapsulated, sustained release capsule, or a matching overencapsulated placebo (sugar pill) for a period of 78\u2005weeks of treatment. The primary efficacy outcome measure in this study is the change in cognitive function as assessed by the Alzheimer's disease Assessment Scale (ADAS-Cog 12) from baseline to the end of treatment duration (78\u2005weeks). There are two key secondary outcome measures, the Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) and the Disability Assessment for Dementia (DAD). If a statistically significant effect is seen in the primary outcome, CDR-sb will be considered to be a coprimary end point and only the DAD will contribute to the secondary outcome analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study and all subsequent amendments have received ethical approval within each participating country according to national regulations. Each participant will provide written consent to participate in the study. All participants will remain anonymised throughout and the results of the study will be published in an international peer-reviewed journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>EUDRACT Reference Number: 2012-002764-27.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2014-006364","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T22:07:17Z","timestamp":1412892437000},"page":"e006364","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease"],"prefix":"10.1136","volume":"4","author":[{"given":"Brian","family":"Lawlor","sequence":"first","affiliation":[{"name":"Mercer's Institute for Research on Ageing, St. James's Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Kennelly","sequence":"additional","affiliation":[{"name":"Mercer's Institute for Research on Ageing, St. James's Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"O'Dwyer","sequence":"additional","affiliation":[{"name":"Mercer's Institute for Research on Ageing, St. James's Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Cregg","sequence":"additional","affiliation":[{"name":"Trinity College Dublin (TCD), Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathal","family":"Walsh","sequence":"additional","affiliation":[{"name":"Trinity College Dublin (TCD), Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Coen","sequence":"additional","affiliation":[{"name":"Mercer's Institute for Research on Ageing, St. James's Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose Anne","family":"Kenny","sequence":"additional","affiliation":[{"name":"Mercer's Institute for Research on Ageing, St. James's Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Howard","sequence":"additional","affiliation":[{"name":"King's College London (KCL), London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Murphy","sequence":"additional","affiliation":[{"name":"King's College London (KCL), London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Adams","sequence":"additional","affiliation":[{"name":"King's College London (KCL), London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Daly","sequence":"additional","affiliation":[{"name":"University College Dublin (UCD), Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Segurado","sequence":"additional","affiliation":[{"name":"University College Dublin (UCD), Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siobhan","family":"Gaynor","sequence":"additional","affiliation":[{"name":"Molecular Medicine Ireland (MMI), Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Crawford","sequence":"additional","affiliation":[{"name":"Archer Pharmaceuticals Inc, 2040 Whitefield Avenue, Sarasota, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mullan","sequence":"additional","affiliation":[{"name":"Archer Pharmaceuticals Inc, 2040 Whitefield Avenue, Sarasota, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"Lucca","sequence":"additional","affiliation":[{"name":"IRCCS\u2014Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d (IRFMN), Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Banzi","sequence":"additional","affiliation":[{"name":"IRCCS\u2014Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d (IRFMN), Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Pasquier","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Regional et Universitaire de Lille (CHRU- LILLE), Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Breuilh","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Regional et Universitaire de Lille (CHRU- LILLE), Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Riepe","sequence":"additional","affiliation":[{"name":"Universitaet Ulm, (UULM), Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janos","family":"Kalman","sequence":"additional","affiliation":[{"name":"Szegedi Tudomanyegyetem (SZEGED), Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Wallin","sequence":"additional","affiliation":[{"name":"G\u00f6teborgs Universitet (UGOT), Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Borjesson","sequence":"additional","affiliation":[{"name":"G\u00f6teborgs Universitet (UGOT), Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Molloy","sequence":"additional","affiliation":[{"name":"University College Cork (UCC), Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magda","family":"Tsolaki","sequence":"additional","affiliation":[{"name":"Aristotle University of Thessaloniki (AUTH), Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Olde Rikkert","sequence":"additional","affiliation":[{"name":"Radboud Alzheimer Centre; Radboud University Medical Centre, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,10,9]]},"reference":[{"key":"2025121510591250000_4.10.e006364.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-051X.1990.tb01059.x"},{"key":"2025121510591250000_4.10.e006364.2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/00005344-198311000-00024","article-title":"Comparison of the cardiovascular effect of FR34235, a new dihydropyridine, with other calcium antagonists","volume":"5","author":"Ohtsuka","year":"1983","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025121510591250000_4.10.e006364.3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2119\/molmed.2010.00180","article-title":"Selective antihypertensive dihydropyridines lower A\u03b2 accumulation by targeting both the production and the clearance of A\u03b2 across the blood-brain barrier","volume":"17","author":"Paris","year":"2011","journal-title":"Mol Med"},{"key":"2025121510591250000_4.10.e006364.4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0021-5198(19)39726-4","article-title":"The effect of nilvadipine, a dihydropyridine type calcium channel blocker, on local cerebral blood flow in rats","volume":"58","author":"Furuichi","year":"1992","journal-title":"Jpn J Pharmacol"},{"key":"2025121510591250000_4.10.e006364.5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s002280050717","article-title":"Nilvadipine protects low-density lipoprotein cholesterol from in vivo oxidation in hypertensive patients with risk factors for atherosclerosis","volume":"56","author":"Inouye","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"2025121510591250000_4.10.e006364.6","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3109\/10641969909052196","article-title":"Effects of nilvadipine on cytokine levels and soluble factors in collagen complicated with essential hypertension","volume":"21","author":"Kagawa","year":"1999","journal-title":"Clin Exp Hypertens"},{"key":"2025121510591250000_4.10.e006364.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03086-4"},{"key":"2025121510591250000_4.10.e006364.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2004.03.009"},{"key":"2025121510591250000_4.10.e006364.9","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1851"},{"key":"2025121510591250000_4.10.e006364.10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/gps.2735","article-title":"Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients-an open-label trial","volume":"27","author":"Kennelly","year":"2012","journal-title":"Int J Geriatr Psychiatry"},{"key":"2025121510591250000_4.10.e006364.11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/gps.2638","article-title":"Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study","volume":"10","author":"Kennelly","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"key":"2025121510591250000_4.10.e006364.12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"2025121510591250000_4.10.e006364.13","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.18.2046"},{"key":"2025121510591250000_4.10.e006364.14","unstructured":"L\u00f3pez-Arrieta JM , Birks J . Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002;(3):CD000147."},{"key":"2025121510591250000_4.10.e006364.15","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(90)90050-C"},{"key":"2025121510591250000_4.10.e006364.16","first-page":"3","article-title":"Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease","volume":"63","author":"Gold","year":"2007","journal-title":"J Clin Psyhiatry"},{"key":"2025121510591250000_4.10.e006364.17","doi-asserted-by":"crossref","unstructured":"Alzheimer's Association, 2010 Alzheimer's Disease Facts and Figures, Alzheimer's & Dementia, 2010 Volume 6. 2010. http:\/\/www.alz.org","DOI":"10.1016\/j.jalz.2010.01.009"},{"key":"2025121510591250000_4.10.e006364.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2011.11.008"},{"key":"2025121510591250000_4.10.e006364.19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm236"}],"updated-by":[{"DOI":"10.1136\/bmjopen-2014-006364corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T00:00:00Z","timestamp":1443398400000}}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2014-006364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:59:19Z","timestamp":1765825159000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2014-006364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,9]]},"published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1136\/bmjopen-2014-006364"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2014-006364","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}